Home
Archive
Contact
✕
Proteasome inhibitors
Home
Proteasome inhibitors
Filter by
Categories
Tags
Authors
Show all
All
Active Clinical Trials
From the Co-Chairs
Institution Spotlights
News in Brief
People
Special Topics
Trial Results
All
AACR
Acute lymphoblastic leukemia
Acute myeloid leukemia
Adolescents and young adults
Advanced practice providers
Advocacy
Anal cancer
ARPA-H
ASCO
Big data
Bladder cancer
Blood cancer
Blood cancers
Breast cancer
Cancer
Cancer care delivery research
Cancer control
Cancer research
Cancer screening
Cancer surveillance
Cardiotoxicity
Chemotherapy
Chronic lymphocytic leukemia
Chronic myeloid leukemia
Clinical trials
Colorectal cancer
ComboMATCH
Comis symposium
Communication
COVID-19
Data science
De-escalation
Diversity
Esophagus cancer
Ethics
Financial hardship
Gallbladder cancer
Gender equity
Genomics
Geriatric oncology
GI cancer
Green tea catechins
Group Meeting
GU cancer
Head and neck cancer
Head and neck squamous cell carcinoma
Health care administration
Health equity
Immunotherapy
In memory
Kidney cancer
Language
Leadership
Leukemia
Liver cancer
Lung cancer
Lung inflammation
Lymphoma
Mammography
Meetings
Melanoma
Mentorship
Mesothelioma
Multiple myeloma
Myelodysplastic syndromes
Myeloma
National Cancer Act
Natural language processing
NCI
NCI-MATCH
NCORP
Neuroendocrine tumors
Non-small cell lung cancer
Older adults
Ovarian cancer
Pancreatic cancer
Pancreatic cyst
Pancreatic cysts
Pathology
Patient-reported outcomes
Peripheral neuropathy
Personalized medicine
Personalized screening
Pneumonitis
Precision medicine
Prevention
Prostate cancer
Proteasome inhibitors
Racism
Radiology
Real-world data
Recurrence
Renal cell
Renal cell carcinoma
Reproductive health
Research results
Sarcoma
Sexuality
Side effects
Smoking cessation
Smoldering multiple myeloma
Social determinants of health
Stomach cancer
Survivorship
Symptom control
Symptom management
Targeted therapy
Throat cancer
TMIST
Tobacco cessation
Translational research
Urinary tract cancer
Vaccination
Women in oncology
All
Akshay Hanikhindi
Diane Dragaud
ECOG-ACRIN Staff
Katie Heller
August 17, 2021
August 17, 2021
Categories
Active Clinical Trials
Now Enrolling: EAA171/OPTIMUM for Myeloma
This randomized phase III trial aims to determine if the addition of ixazomib to lenalidomide improves overall survival in patients with multiple myeloma
![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
